아미쿠스 테라 (FOLD)

Shares of Amicus Therapeutics (FOLD) dropped by 12.19% from $11.36 to $9.98 in the trading on Thursday, Novemeber 9, 2023. The reason why FOLD down is due to an inisder trading. The company's President, Bradley Campbell, sold 11,700 shares of Amicus Therapeutics stock, which likely contributed to the negative sentiment and the subsequent drop in share price. This insider transaction raised concerns among investors and may have eroded confidence in the company's prospects, resulting in the significant share price decline.

Amicus Therapeutics Stock (FOLD) dropped by 9.29% from $12.16 to $11.03 in the trading on Monday October 2, 2023. The reasons why stock FOLD is down today includes:

• Recent FDA Requests: Regulators asked for more information on its experimental pill treatment for Fabry disease. The FDA's request means that Amicus will not be able to file for U.S. approval by its previously announced target of the end of the year, which is the reason why FOLD stock is down.
• Financing Collaboration: Amicus Therapeutics has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone.

Amicus Therapeutics Stock (FOLD) fell 7.92% to $11.86 after announcing FDA approval and launch of new treatment for pompe disease.

https://www.globenewswire.com/news-release/2023/09/28/2751407/15991/en/Amicus-Therapeutics-Announces-FDA-Approval-and-Launch-of-New-Treatment-for-Pompe-Disease.html